No Prescription |
 |
 | ||
|
MOBIC Generic Meloxicam |
|
| ||
No Prescription » Prescription Drugs 11 » MOBIC Generic Meloxicam Product Origin: EU (Turkey)This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English.Medical Information:Mobic is used for: Treating rheumatoid arthritis osteoarthritis and juvenile arthritis. Meloxicam is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Meloxicam works by reducing hormones that cause inflammation and pain in the body. Meloxicam is used to treat pain or inflammation caused by arthritis. Nonsteroidal anti-inflammatory drugs (also called NSAIDs) are used to relieve some symptoms caused by arthritis (rheumatism) such as inflammation swelling stiffness and joint pain. However this medicine does not cure arthritis and will help you only as long as you continue to take it.Some of these medicines are also used to relieve other kinds of pain or to treat other painful conditions such as:gout attacks; bursitis; tendinitis; sprains strains or other injuries; or menstrual cramps. Buy MOBIC Generic Meloxicam and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About MOBIC Generic Meloxicam: Product Type: Prescription Drugs 11 MOBIC ( Generic Meloxicam ) MOBIC (Generic Meloxicam) Generic Meloxicam 15mg Generic Meloxicam MOBIC
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
